Czech/SlovakiaCzech RepublicSlovakia

Catching up on the biotech revolution

16.09.2006

In order to keep track of developments and to promote network-creation, for both domestic-domestic and domestic-foreign cooperations the South Moravian Innovation Centre, Brno, has conducted the Czech Republic’s first comprehensive biotech survey which follows OECD recommendations. Its findings are presented in the Czech Biotech Report 2006. The report testifies that the Czech biotech sector is developing at a rapid pace. A long history of biotechnology research and development has secured the country a strong position in a number of technological areas, including industrial biotechnology and health care.

Experts from the South Moravian Innovation Centre have identified 120 biotechnology companies in the Czech Republic. In line with current OECD recommendations, 55 companies, predominantly from traditional food, beverages and brewing industries, were omitted from the survey. From the remaining 65 biotechnology companies, 20 were identified as ‘dedicated’ Czech biotechnology firms, 11 as subsidiaries of foreign dedicated biotech firms and 34 as so-called innovative biotech firms (biotech business units of otherwisely diversified companies). Besides private enterprises and corporations, the report names 220 universities and biotechnology research institutes in the country.
The authors see the Czech Republic’s biggest advantage in its tight academic network of universities and research in stitutes that is spread accross the whole country, instead of being mainly concentrated around the capital region of Prague. In 2005, according to the report, 56,777 students were enrolled on life science courses at universities, with an output of 7,400 graduates annually.
Development of distinct clusters
Prague is, and always has been, a centre for

research and development, and the capital region maintains its attraction as a strong

biotech location. Prague and Central Bohemia are home to 4 in 10 of the biotech companies and to almost half of all universities and biotech research institutes.
Another important cluster is forming around the city of Brno in Southern Moravia, which has a strong tradition in medical research, particularly with cancer and cardiovascular diseases. Brno enjoys an excellent infrastructure, a strong academic network and encourangement from the local government. It is home to roughly one-fifth of the companies and research institutes identified in the report.
Broad expertise
The survey of the companies’ and research institutes’ ‘biotechnology techniques’ and ‘biotechnology applications’ points to a very broad expertise within the Czech biotech community, and accross all disciplines. Still, companies concentrate their activities in the sectors of environment (83%), microbial and cell biotechnology (81%) and human/veterinary diagnostics (63%). The three sectors in which Czech research institutes are most active in are plant biotechnology (96%), microbial and cell biotechnology (40%) and animal biotechnology (39%).
Contact:
South Moravian Innovation Centre – JIC
U Vodárny 2, 616 00 Brno, Czech Republic
Tel./Fax: +420-541-1430-00 /-11
www.gate2biotech.com, www.jic.cz

Czech/SlovakiaCzech RepublicSlovakia

07.03.2012

The Czech government has beefed up its investments in biotech with the help of EU structural funds. In February, the country’s Education Minister Josef Dobes gave the go-ahead for the Biocev centre in Vestec near Prague. Although...

Czech/SlovakiaCzech RepublicSlovakia

05.12.2011

Brno – Czech Prime Minister Petr Necas has officially inaugurated the first of six European Technology Institutes slated to be launched in the Czech Republic with help from European FEDER funds. Although construction of the €200m...

Czech/SlovakiaCzech RepublicSlovakia

01.10.2011

Prague – Czech drug developer VUAB Pharma a.s. has joined CzechBio. The company, which has its headquarters in Roztoky near Prague, became the 35th member of the Czech biotechnology industry association in September. VUAB...

Czech/SlovakiaCzech RepublicSlovakia

09.08.2011

Praque – A team of researchers headed by Dr. Valdimir Kral, Director of Chemical Development at Sanofi-Aventis’ Czech research unit Zentiva Development sro, has presented a new targeted drug delivery system that couples combined...

Czech/SlovakiaCzech RepublicSlovakia

01.06.2011

Brno – Plans for building a Central European Insitute of Technology (CEITEC) in Brno look set to take a big step closer to becoming reality. In mid-May, CEITEC representatives announced that EU financing for the EUR260m...

Czech/SlovakiaCzech RepublicSlovakia

03.11.2010

Plzen – Czech antibody discovery and development specialist AbCheck s.r.o. has signed its first contract with a big pharma company. In October, the yearling Czech spin-off from German antibody drug developer Affimed GmbH...

Czech/SlovakiaCzech RepublicSlovakia

13.09.2010

Prague – CzechInvest has called on Czech high-tech companies in the field of ICT, bio­technology, clean technology and micro­electronics to apply for the Czech Technology Accelerator programme. Under the third call, which was...

Czech/SlovakiaCzech RepublicSlovakia

02.07.2010

Prague – Czech researchers from Charles University in Prague have discovered a molecular biomarker that helps to predict toxicity and a higher risk for adverse effects in children with juvenile arthritis that are treated with...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2010

Prague – Czech biotech company Lenti­Kats AS has begun worldwide commercialisation of a patented, cost-effective encapsulation technology for use in the food and bio­pharmaceuticals industry. The company has discovered a way to...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2010

Sofia – Bulgaria’s parliament has approved a law that will in effect ban any cultivation of GMO crops in the country. “There will be no field on the country’s territory where GMOs can be cultivated,” said Kostadin Yazov from the...

Displaying results 1 to 10 out of 70

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-czech-slovakia/article/catching-up-on-the-biotech-revolution.html

Events

All Events

Stock list

All quotes

TOP

  • BIOINVENT INTERNATIONAL AB (S)3.10 SEK9.15%
  • Allergy Therapeutics (UK)19.12 GBP6.94%
  • PHARMING (NL)0.48 EUR6.67%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • CHRONTECH PHARMA (S)0.07 SEK-12.50%

TOP

  • WILEX (D)3.15 EUR314.5%
  • SANTHERA (CH)68.55 CHF90.4%
  • ADDEX (CH)4.08 CHF82.1%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.83 EUR-26.8%
  • PROSENSA (NL)9.48 USD-25.2%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP729.1%
  • PAION (D)2.79 EUR316.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • PROSENSA (NL)9.48 USD-68.0%

No liability assumed, Date: 25.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products